Hospital care direct costs due to ambulatory care sensitive conditions related to diabetes mellitus in the Mexican public healthcare system.

BACKGROUND: Hospitalizations for ambulatory care sensitive conditions (ACSC) incur substantial costs on the health system that could be partially avoided with adequate outpatient care. Complications of chronic diseases, such as diabetes mellitus (DM), are considered ACSC. Previous studies have shown that hospitalizations due to diabetes have a significant financial burden. In Mexico, DM is a major health concern and a leading cause of death, but there is limited evidence available. This study aimed to estimate the direct costs of hospitalizations by DM-related ACSC in the Mexican public health system. METHODS: We selected three hospitals from each of Mexico's main public institutions: the Mexican Social Security Institute (IMSS), the Ministry of Health (MoH), and the Institute of Social Security and Services for State Workers (ISSSTE). We employed a bottom-up microcosting approach from the healthcare provider perspective to estimate the total direct costs of hospitalizations for DM-related ACSC. Input data regarding length of stay (LoS), consultations, medications, colloid/crystalloid solutions, procedures, and laboratory/medical imaging studies were obtained from clinical records of a random sample of 532 hospitalizations out of a total of 1,803 DM-related ACSC (ICD-10 codes) discharges during 2016. RESULTS: The average cost per DM-related ACSC hospitalization varies among institutions, ranging from $1,427 in the MoH to $1,677 in the IMSS and $1,754 in the ISSSTE. The three institutions' largest expenses are LoS and procedures. Peripheral circulatory and renal complications were the major drivers of hospitalization costs for patients with DM-related ACSC. Direct costs due to hospitalizations for DM-related ACSC in these three institutions represent 1% of the gross domestic product (GDP) dedicated to health and social services and 2% of total hospital care expenses. CONCLUSIONS: The direct costs of hospitalizations for DM-related ACSC vary considerably across institutions. Disparities in such costs for the same ACSC among different institutions suggest potential disparities in care quality across primary and hospital settings (processes and resource utilization), which should be further investigated to ensure optimal supply utilization. Prioritizing preventive measures for peripheral circulatory and renal complications in DM patients could be highly beneficial.

Acreditación de servicios y calidad de la atención a neonatos en hospitales mexicanos.

OBJETIVO: Comparar la calidad de atención a neonatos con sepsis neonatal, hipoxia intrauterina, prematuridad y asfixia perinatal en hospitales acreditados (HA) y no acreditados (HNA). Material y métodos. Se evaluaron 28 hospi-tales de la Secretaría de Salud en 11 estados de México; la evaluación incluyó infraestructura, equipamiento e insumos, procesos de gestión de calidad e indicadores de calidad clínica. Se utilizó LQAS y se estimó el cumplimiento promedio de criterios e indicadores en HA y HNA. RESULTADOS: Hubo diferencias significativas en favor de HA en equipamiento e insumos y no significativas en existencia y funcionamiento de los comités hospitalarios. No hubo diferencias consistentes ni significativas en cumplimiento de indicadores clínicos entre los HA y HNA. CONCLUSIONES: La acreditación para la atención de neonatos con los diagnósticos seleccionados no se asocia a diferencias en la calidad de la atención.

Acreditación de servicios y calidad de la atención a neonatos en hospitales mexicanos / Accreditation of services and quality of care for newborns in mexican hospitals

Resumen: Objetivo: Comparar la calidad de atención a neonatos con sepsis neonatal, hipoxia intrauterina, prematuridad y asfixia perinatal en hospitales acreditados (HA) y no acreditados (HNA). Material y métodos: Se evaluaron 28 hospitales de la Secretaría de Salud en 11 estados de México; la evaluación incluyó infraestructura, equipamiento e insumos, procesos de gestión de calidad e indicadores de calidad clínica. Se utilizó LQAS y se estimó el cumplimiento promedio de criterios e indicadores en HA y HNA. Resultados: Hubo diferencias significativas en favor de HA en equipamiento e insumos y no significativas en existencia y funcionamiento de los comités hospitalarios. No hubo diferencias consistentes ni significativas en cumplimiento de indicadores clínicos entre los HA y HNA. Conclusiones: La acreditación para la atención de neonatos con los diagnósticos seleccionados no se asocia a diferencias en la calidad de la atención.

Abstract: Objective: To compare the quality of care for neonates with neonatal sepsis, intrauterine hypoxia, prematurity and perinatal asphyxia in accredited hospitals (HA) and unaccredited (HNA). Materials and methods: 28 hospitals of the Ministry of Health were evaluated in 11 states in Mexico; the evaluation included infrastructure, equipment and supplies, quality management processes, and clinical quality indicators. LQAS was used, and average fulfillment of criteria and indicators in AH and NAH was estimated. Results: There were significant differences in favor of HA in equipment and supplies and, not significant, in the existence and functioning of hospital committees. There were no consistent or significant differences in compliance with clinical indicators between the AH y NAH. Conclusions: Accreditation for the care of newborns with the selected diagnoses is not associated with differences in the quality of care.

Potentially inappropriate prescribing in older adults in Mexico.

OBJECTIVE: To identify and quantify potentially inappropriate prescribing (prescripción potencialmente inapropiada, PPI) and other drug prescribing problems in public health care services in a population-based study at the three existing levels of complexity in Mexico. METHODS: Descriptive analysis of the Study on Satisfaction of Users of the Social Protection System in Health 2014-2016, prescription and drug supply section, to obtain the prevalence of PPI in older adults (≥ 65 years), based on Beers, STOPP, Prescrire and BSP listings using AM (older adults) prescription indicators, one for each listing. RESULTS: Most older adults (67%) were prescribed at least one medication, with a mean of 2.7 medications per prescription. The PPI prevalence was 74% according to the BSP criteria, 67% according to the STOPP listing, 59% with the Beer criteria, and 20% with Prescrire. The most frequent PPI prescriptions were NSAIDs, vasodilators and sulfonylureas. CONCLUSIONS: The use of PPIs in AM is high in Mexico. The higher prevalence found in this study may reflect the use of a source with population representativeness. The partial use and adaptations of the criteria make difficult comparing the studies; however, the STOPP criteria are the ones with the highest prevalence, as they cover a greater number of drugs and their use is more common in the first level of care.

Potentially inappropriate prescribing in older adults in Mexico / Prescripción potencialmente inapropiada en adultos mayores en México

ABSTRACT OBJECTIVE To identify and quantify potentially inappropriate prescribing (prescripción potencialmente inapropiada, PPI) and other drug prescribing problems in public health care services in a population-based study at the three existing levels of complexity in Mexico. METHODS Descriptive analysis of the Study on Satisfaction of Users of the Social Protection System in Health 2014-2016, prescription and drug supply section, to obtain the prevalence of PPI in older adults (≥ 65 years), based on Beers, STOPP, Prescrire and BSP listings using AM (older adults) prescription indicators, one for each listing. RESULTS Most older adults (67%) were prescribed at least one medication, with a mean of 2.7 medications per prescription. The PPI prevalence was 74% according to the BSP criteria, 67% according to the STOPP listing, 59% with the Beer criteria, and 20% with Prescrire. The most frequent PPI prescriptions were NSAIDs, vasodilators and sulfonylureas. CONCLUSIONS The use of PPIs in AM is high in Mexico. The higher prevalence found in this study may reflect the use of a source with population representativeness. The partial use and adaptations of the criteria make difficult comparing the studies; however, the STOPP criteria are the ones with the highest prevalence, as they cover a greater number of drugs and their use is more common in the first level of care.

RESUMEN OBJETIVO Identificar y cuantificar la prescripción potencialmente inapropiada (PPI) y otros problemas en la prescripción de medicamentos en los servicios públicos de atención médica en un estudio poblacional en los tres niveles de complejidad existentes en México. MÉTODOS Análisis descriptivo del Estudio de Satisfacción de Usuarios del Sistema de Protección Social en Salud 2014-2016, sección de prescripción y surtimiento de medicamentos, para obtener la prevalencia de PPI en adultos mayores (≥ 65 años) con base en listados Beers, STOPP, Prescrire y BSP mediante indicadores de prescripción en AM, uno por cada listado. RESULTADOS Al 67% de los AM se les prescribió al menos un medicamento, con una media de 2.7 medicamentos por receta. La prevalencia de PPI fue del 74% según los criterios BSP, del 67% según el listado STOPP, del 59% con los criterios Beer y del 20% con Prescrire. Las prescripciones PPI más frecuentes fueron los AINES, vasodilatadores y las sulfonilureas. CONCLUSIONES El uso de PPI en AM es alto en México. La mayor prevalencia encontrada en este estudio puede ser reflejo de la utilización de una fuente con representatividad poblacional. La utilización parcial y adaptaciones de los criterios dificultan la comparabilidad entre estudios, sin embargo, los criterios STOPP son los que más altas prevalencias han presentado debido a que abarca un mayor número de medicamentos y su uso más habitual en el primer nivel de atención.

[Polypharmacy in Mexico: a challengefor prescription quality]. / Polifarmacia en México: un reto para la calidad en la prescripción.

OBJECTIVE: To analyze the prevalence of polypharmacy, as well as the factors that identify the groups with higher risk, in population study in Mexico. MATERIALS AND METHODS: Descriptive analysis of the Encuesta Nacional de Salud y Nutrición 2018-19 (Ensanut 2018-19), Utilization of services (medicine section) and Household questionnaires, to obtain prevalence of polypharmacy (simultaneous consumption ≥5 medicines). A logistic regression model was used to estimate the association of polypharmacy with sociodemographic and health care factors. RESULTS: Prevalence of polypharmacy: 18 years, 15.5%, and 65 years, 26.5%. Higher prevalence in: nephropathies (61.5%), heart disease (42.2%), chronic ob-structive pulmonary disease (38.5%), diabetes (29.3%) and hypertension (26.4%). Increased possibility in adults 65 years (OR:1.95), low schooling (OR:1.54), social security (OR:1.64), serviced in public services (OR:1.7) and chronic illness (OR:1.84). CONCLUSIONS: Polypharmacy is associated with chronic disease and some sociodemographic factors. Large area of opportunity to improve quality of care, particularly pharmacological prescription to identified population with higher risk.

OBJETIVO: Analizar la prevalencia de polifarmacia, así como los factores que identifican a los grupos con mayor riesgo, en un estudio poblacional en México. MATERIAL Y MÉTODOS: Salud y Nutrición 2018-19 (Ensanut 2018-19), cuestionarios de Utilización de servicios (sección medicamentos) y del Hogar, para obtener la prevalencia de polifarmacia (consu-mo simultáneo ≥5 medicamentos). Se utilizó un modelo de regresión logística para estimar la asociación de polifarmacia con factores sociodemográficos y de atención a la salud. RESULTADOS: Prevalencia de polifarmacia: ≥18 años, 15.5%, y ≥65 años, 26.5%. Prevalencias superiores: nefropatías (61.5%), cardiopatías (42.2%), enfermedad pulmonar obstructiva crónica (38.5%), diabetes (29.3%) e hipertensión (26.4%). Mayor posibilidad en adultos ≥65 años (OR:1.95), con baja escolaridad (OR:1.54), seguridad social (OR:1.64), atendidos en servicios públicos (OR:1.7) y enfermedad crónica (OR:1.84). CONCLUSIONES: La polifarmacia se asocia con tener enfermedad crónica y con factores sociodemográficos. Es una gran área de oportunidad para mejorar calidad de la atención, particularmente la prescripción farmacológica a la población identificada con mayor riesgo.

Polifarmacia en México: un reto para la calidad en la prescripción / Polypharmacy in Mexico: a challenge for prescription quality

Resumen: Objetivo: Analizar la prevalencia de polifarmacia, así como los factores que identifican a los grupos con mayor riesgo, en un estudio poblacional en México. Material y métodos: Análisis descriptivo de la Encuesta Nacional de Salud y Nutrición 2018-19 (Ensanut 2018-19), cuestionarios de Utilización de servicios (sección medicamentos) y del Hogar, para obtener la prevalencia de polifarmacia (consumo simultáneo ≥5 medicamentos). Se utilizó un modelo de regresión logística para estimar la asociación de polifarmacia con factores sociodemográficos y de atención a la salud. Resultados: Prevalencia de polifarmacia: ≥18 años, 15.5%, y ≥65 años, 26.5%. Prevalencias superiores: nefropatías (61.5%), cardiopatías (42.2%), enfermedad pulmonar obstructiva crónica (38.5%), diabetes (29.3%) e hipertensión (26.4%). Mayor posibilidad en adultos ≥65 años (OR:1.95), con baja escolaridad (OR:1.54), seguridad social (OR:1.64), atendidos en servicios públicos (OR:1.7) y enfermedad crónica (OR:1.84). Conclusiones: La polifarmacia se asocia con tener enfermedad crónica y con factores sociodemográficos. Es una gran área de oportunidad para mejorar calidad de la atención, particularmente la prescripción farmacológica a la población identificada con mayor riesgo.

Abstract: Objective: To analyze the prevalence of polypharmacy, as well as the factors that identify the groups with higher risk, in population study in Mexico. Materials and Methods: Descriptive analysis of the Encuesta Nacional de Salud y Nutrición 2018-19 (Ensanut 2018-19), Utilization of services (medicine section) and Household questionnaires, to obtain prevalence of polypharmacy (simultaneous consumption ≥5 medicines). A logistic regression model was used to estimate the association of polypharmacy with sociodemographic and health care factors. Results: Prevalence of polypharmacy: 18 years, 15.5%, and 65 years, 26.5%. Higher prevalence in: nephropathies (61.5%), heart disease (42.2%), chronic obstructive pulmonary disease (38.5%), diabetes (29.3%) and hypertension (26.4%). Increased possibility in adults 65 years (OR:1.95), low schooling (OR:1.54), social security (OR:1.64), serviced in public services (OR:1.7) and chronic illness (OR:1.84). Conclusions: Polypharmacy is associated with chronic disease and some sociodemographic factors. Large area of opportunity to improve quality of care, particularly pharmacological prescription to identified population with higher risk.